Literature DB >> 19498412

Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib.

Lauren C Harshman1, Sandy Srinivas, Aya Kamaya, Benjamin I Chung.   

Abstract

BACKGROUND: A 57-year-old woman presented to the emergency department at a community hospital with a 2-month history of fatigue and right-sided flank and abdominal pain. Noncontrast CT of the abdomen and pelvis revealed a 9.1 cm right renal mass. INVESTIGATIONS: Contrast CT of the chest, abdomen and pelvis, MRI of the abdomen and pelvis with gadolinium, radionuclide bone scan, lung nodule biopsy, complete blood count, comprehensive metabolic profile, and measurement of serum lactate dehydrogenase. DIAGNOSIS: Stage IV, T3bN0M1 clear cell renal cell carcinoma, with an associated tumor thrombus extending into the vena cava. MANAGEMENT: The patient was treated with neoadjuvant sunitinib, which resulted in a marked response in the primary tumor and metastatic lesions as well as regression of the tumor thrombus well into the renal vein. Thus, laparoscopic radical nephrectomy was feasible and was achieved without hemorrhagic or wound healing complications. One month after surgery, she had evidence of disease progression in the lung and a periaortic lymph node. She was restarted on sunitinib with resultant disease stabilization, but discontinued the drug owing to toxicity. Eight months after cessation of sunitinib, she received a dendritic cell vaccine. She remains alive without evidence of disease progression 2 years after her diagnosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19498412     DOI: 10.1038/nrurol.2009.84

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  36 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

Review 3.  Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.

Authors:  Christopher G Wood
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

4.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 6.  Cytotoxic chemotherapy for advanced renal cell carcinoma.

Authors:  A Yagoda; D Petrylak; S Thompson
Journal:  Urol Clin North Am       Date:  1993-05       Impact factor: 2.241

7.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma.

Authors:  Tarek M Mekhail; Rony M Abou-Jawde; Gabriel Boumerhi; Sareena Malhi; Laura Wood; Paul Elson; Ronald Bukowski
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

8.  Long-term results of resection of renal cell cancer with extension into inferior vena cava.

Authors:  J A Libertino; L Zinman; E Watkins
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

9.  Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.

Authors:  Anil A Thomas; Brian I Rini; Brian R Lane; Jorge Garcia; Robert Dreicer; Eric A Klein; Andrew C Novick; Steven C Campbell
Journal:  J Urol       Date:  2008-12-18       Impact factor: 7.450

10.  Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma.

Authors:  M M Walther; R B Alexander; G H Weiss; D Venzon; A Berman; H I Pass; W M Linehan; S A Rosenberg
Journal:  Urology       Date:  1993-09       Impact factor: 2.649

View more
  10 in total

Review 1.  [Systemic and surgical management of metastatic renal cell carcinoma].

Authors:  M W Kramer; A S Merseburger; I Peters; S Waalkes; M A Kuczyk
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

2.  Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial.

Authors:  Jose A Karam; Catherine E Devine; Bryan M Fellman; Diana L Urbauer; E Jason Abel; Mohamad E Allaf; Axel Bex; Brian R Lane; R Houston Thompson; Christopher G Wood
Journal:  BJU Int       Date:  2015-06-29       Impact factor: 5.588

3.  Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma.

Authors:  Hironori Fukuda; Tsunenori Kondo; Toshio Takagi; Jumpei Iizuka; Yoji Nagashima; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2017-04-01       Impact factor: 3.402

4.  Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma.

Authors:  Jing Wang; Shuzhi Wu; Tianren Huang
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

Review 5.  The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma.

Authors:  Leonardo D Borregales; Mehrad Adibi; Arun Z Thomas; Christopher G Wood; Jose A Karam
Journal:  Ther Adv Urol       Date:  2015-11-20

6.  Use of a combined retroperitoneoscopic and transperitoneal laparoscopic technique for the management of renal cell carcinoma with level I tumor thrombi.

Authors:  Oner Sanli; Tzevat Tefik; Selcuk Erdem; Tayfun Oktar; Murat Tunc; Faruk Ozcan
Journal:  J Minim Access Surg       Date:  2013-10       Impact factor: 1.407

7.  Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center.

Authors:  Shingo Hatakeyama; Takahiro Yoneyama; Itsuto Hamano; Hiromi Murasawa; Takuma Narita; Masaaki Oikawa; Kazuhisa Hagiwara; Daisuke Noro; Toshikazu Tanaka; Yoshimi Tanaka; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama
Journal:  BMC Urol       Date:  2013-10-14       Impact factor: 2.264

8.  Efficacy and safety of perioperative appliance of sunitinib in patients with metastatic or advanced renal cell carcinoma: A systematic review and meta-analysis.

Authors:  Hongyu Jin; Jing Zhang; Kai Shen; Jianqi Hao; Yuying Feng; Chi Yuan; Yuqi Zhu; Xuelei Ma
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

9.  Surgical treatment for Xp11.2 translocation renal cell carcinoma with venous thrombus: A STROBE-compliant study.

Authors:  Liyuan Ge; Xiaojun Tian; Jing Ma; Guojiang Zhao; Yimeng Song; Shudong Zhang; Lulin Ma
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

10.  Postoperative radiotherapy to stabilize a tumor embolus in clear cell renal cell carcinoma: A case report.

Authors:  Zhi-Hua Gong; Lv-Jun Yan; Jian-Guo Sun
Journal:  Oncol Lett       Date:  2014-08-05       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.